Mythanh Hang
Family · Houston, TXNPI 1144612631
Payments from drug & device makers
Across 318 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$768
- GSK$521
- AstraZeneca$514
- Bayer$462
- Lilly USA, LLC$404
- AbbVie$346
- plus $3K from 26 others
What the payments were for
- Food & beverage$5,677100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $768 |
| GSK | 29 | $521 |
| AstraZeneca | 30 | $514 |
| Bayer | 24 | $462 |
| Lilly USA, LLC | 24 | $404 |
| AbbVie | 22 | $346 |
| Amgen | 18 | $309 |
| Eisai Inc. | 10 | $211 |
| Nestle Healthcare Nutrition Inc. | 6 | $195 |
| Esperion Therapeutics, Inc. | 12 | $192 |
| Pfizer | 10 | $189 |
| Boehringer Ingelheim | 11 | $187 |
| Biohaven Pharmaceuticals, Inc. | 13 | $183 |
| Merck | 12 | $166 |
| Exact Sciences | 8 | $155 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $134 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $104 |
| Amarin Pharma, Inc. | 5 | $96 |
| Johnson & Johnson | 5 | $75 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Dexcom, Inc. | 2 | $60 |
| Azurity Pharmaceuticals, Inc. | 3 | $59 |
| Gilead | 2 | $53 |
| Abbott | 2 | $39 |
| Shield Therapeutics Inc | 2 | $33 |
| Almatica Pharma LLC | 1 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Mannkind Corporation | 1 | $23 |
| Tolmar, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $10 |
How this compares
$5,677 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $58,995 |
| ProliaDenosumab | 28 | $49,247 |
| FarxigaDapagliflozin Propanediol | 39 | $44,386 |
| OzempicSemaglutide | 22 | $37,178 |
| VascepaIcosapent Ethyl | 41 | $36,723 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $23,641 |
| MyrbetriqMirabegron | 20 | $20,346 |
| Nurtec OdtRimegepant Sulfate | 11 | $14,221 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,223 |
| Icosapent Ethyl | 14 | $3,418 |
| Omega-3 Acid Ethyl Esters | 22 | $2,936 |
| Atorvastatin Calcium | 443 | $2,569 |
| Celecoxib | 51 | $1,909 |
| Metoprolol Succinate | 108 | $1,799 |
| Clobetasol Propionate | 81 | $1,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $187 | $58,99535 claims |
| AmgenProlia | $309 | $49,24728 claims |
| AstraZenecaFarxiga | $514 | $44,38639 claims |
| Novo NordiskOzempic | $768 | $37,17822 claims |
| GSKTrelegy Ellipta | $521 | $23,64129 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $20,34620 claims |
| PfizerNurtec Odt | $189 | $14,22111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.